Scilex Holding (SCLX) Capital Expenditure: History & Chart

Scilex Holding Company(SCLX)

Drug Manufacturers - General · Palo Alto, CA

$3.96+0.14 (+3.66%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Scilex Holding Company

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Palo Alto, CA

34 employees

www.scilexholding.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Henry H. Ji

View full financials

Capital Expenditures

The latest quarterly capex is $2.46 Million. Capital Expenditures (CapEx) represents spending on physical assets like property, plant, equipment, and technology infrastructure. It's the investment in the company's future productive capacity.

Q2 FY2026 (2026-06-30).

Depreciation|PP&E|Free Cash Flow|Acquisitions|Cash Flow

CapEx

SCLX CapEx

$2.46M

Reported quarterly capital expenditures; no daily interpolation. Q2 FY2026 (2026-06-30): $2.46M.

+1782.88% over 10Y

Current CapEx

$2.46M

$2.46 Million

Q2 FY2026 · 2026-06-30

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly CapEx History

Period	CapEx	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$2.46M	N/A	N/A
Q1 FY2026Period end 2026-03-31	−$3.05M	-2174.93%	-1933.33%
Q4 FY2025Period end 2025-12-31	−$134.07K	N/A	+10.62%
Q3 FY2025Period end 2025-09-30	$300.00K	N/A	N/A
Q2 FY2025Period end 2025-06-30	−$4.07	+100.00%	+100.00%
Q1 FY2025Period end 2025-03-31	−$150.00K	0.00%	0.00%
Q4 FY2024Period end 2024-12-31	−$150.00K	0.00%	+49.90%
Q3 FY2024Period end 2024-09-30	−$150.00K	0.00%	+3.23%
Q2 FY2024Period end 2024-06-30	−$150.00K	0.00%	N/A
Q1 FY2024Period end 2024-03-31	−$150.00K	+49.90%	N/A
Q4 FY2023Period end 2023-12-31	−$299.42K	-93.17%	N/A
Q3 FY2023Period end 2023-09-30	−$155.00K	N/A	N/A
Q2 FY2023Period end 2023-06-30	−$8.00K	N/A	N/A
Q1 FY2023Period end 2023-03-31	$0	N/A	N/A
Q4 FY2022Period end 2022-12-31	−$6.96K	N/A	N/A
Q3 FY2022Period end 2022-09-30	−$6.88K	N/A	N/A
Q2 FY2022Period end 2022-06-30	$4.23	N/A	N/A
Q1 FY2022Period end 2022-03-31	$0	N/A	N/A
Q4 FY2021Period end 2021-12-31	−$0.47	N/A	N/A
Q3 FY2021Period end 2021-09-30	−$4.1	N/A	N/A
Q2 FY2021Period end 2021-06-30	−$0.51	N/A	N/A
Q1 FY2021Period end 2021-03-31	$2	N/A	N/A
Q4 FY2020Period end 2020-12-31	−$6.25K	N/A	+95.72%
Q3 FY2020Period end 2020-09-30	−$6.25K	N/A	+95.72%
Q2 FY2020Period end 2020-06-30	−$6.25K	N/A	+95.72%
Q1 FY2020Period end 2020-03-31	−$6.25K	+95.72%	+95.72%
Q4 FY2019Period end 2019-12-31	−$146.00K	0.00%	N/A
Q3 FY2019Period end 2019-09-30	−$146.00K	0.00%	N/A
Q2 FY2019Period end 2019-06-30	−$146.00K	0.00%	N/A
Q1 FY2019Period end 2019-03-31	−$146.00K	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 30, 2026